Reproxalap (ADX-102) is a novel inhibitor of reactive aldehyde species (RASP) for the treatment of ocular inflammation.
Reproxalap (ADX-102) protected octadecanal (C18:0-al) induced cytotoxicity and apoptosis in cellular model for SLS (Sjögren-Larsson syndrome), also inhibited etabolism of C18:0-al to fatty alcohol (octadecanol).
Reproxalap (ADX-102) is a novel small-molecule RASP inhibitor in development to treat NAU, allergic conjunctivitis, and dry eye disease.
Results from nonclinical studies indicate that reproxalap and related molecules have the potential to mitigate ocular inflammation related to NAU and other inflammatory eye conditions, such as postsurgical inflammation and diabetic retinopathy.
